The Need for Classification Criteria of Immune Checkpoint Inhibitor-induced inflammatory Arthritis: A Scoping Review.

Ghosh, Nilasha; Jivanelli, Bridget; Couette, Nina; Singh, Namrata; Kostine, Marie; Simon Meara, Alexa; Liew, David F L

Ghosh, Nilasha; Jivanelli, Bridget; Couette, Nina; Singh, Namrata; Kostine, Marie; Simon Meara, Alexa; Liew, David F L.

Affiliation

Ghosh N; Department of Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA. Electronic address: ghoshn@hss.edu.
Jivanelli B; Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA.
Couette N; Department of Rheumatology, Rheumatology Care Center, Genesis Healthcare System, 2525 Maple Avenue, Zanesville, OH 43701, USA.
Singh N; Division of Rheumatology, Department of Medicine, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195, USA.
Kostine M; Department of Rheumatology, Bordeaux University Hospital, 311 Président Wilson Boulevard, Bordeaux 33200, France.
Simon Meara A; Division of Oncology, Department of Medicine, The Ohio State University Wexner Medical Center, 460 West 10th Avenue, Columbus, OH 43210, USA.
Liew DFL; Department of Rheumatology, Austin Health; Department of Clinical Pharmacology and Therapeutics, Austin Health; Department of Medicine, University of Melbourne, Level 1, North Wing, 300 Waterdale Road, PO Box 5444, Heidelberg West, Victoria 3081, Australia.

Rheum Dis Clin North Am ; 50(2): 325-335, 2024 May.

Article de En | MEDLINE | ID: mdl-38670730

ABSTRACT

ABSTRACT

Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an immune-related adverse event that can occur as a result of receiving ICIs for cancer treatment. Thus far, ICI-IA has been described variably in the literature, in part due to varying presentations that evolve over time, as well as a lack of standardized definitions and classification. This scoping review aggregates various descriptions of ICI-IA, highlighting the most prominent attributes of ICI-IA from categories such as symptoms, signs, imaging, and laboratory findings as well as discussing potential mimic conditions.

Sujet(s)
Mots clés

Cancer; Immune checkpoint inhibitors; Immune-related adverse events; Immunotoxicity; Inflammatory arthritis

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Arthrite / Inhibiteurs de points de contrôle immunitaires Limites: Humans Langue: En Journal: Rheum Dis Clin North Am / Rheum. dis. clin. North America / Rheumatic disease clinics of North America Sujet du journal: REUMATOLOGIA Année: 2024 Type de document: Article Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google